Company overview
EpicentRx is a biopharmaceutical company developing innovative therapies for oncology and related conditions, including the oncolytic virus-delivered TGFβ inhibitor AdAPT-001 and the small molecule RRx-001 (nibrozetone). Both lead candidates have received FDA Fast Track designations: AdAPT-001 for recurrent/refractory soft tissue sarcoma in combination with checkpoint inhibitors, and RRx-001 for severe oral mucositis prevention and other indications. Their platforms target tumor sensitization, immune modulation, inflammation reduction, and side effect mitigation across cancers like STS, colorectal, breast, and head/neck.
EpicentRx is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include epicentrx, adapt-001, rrx-001, oncolytic virus, tgfβ inhibitor, oral mucositis.
Structured facts
- Website
- https://www.epicentrx.com
- Markets served
- United States & Americas
- Keywords
- epicentrx, adapt-001, rrx-001, oncolytic virus, tgfβ inhibitor, oral mucositis, fda fast track, immunotherapy, soft tissue sarcoma
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are EpicentRx's lead drug candidates?
- AdAPT-001, an oncolytic adenovirus-delivered TGFβ inhibitor for immunotherapy sensitization in cancers like soft tissue sarcoma, and RRx-001 (nibrozetone), a small molecule with anti-inflammatory, Nrf2-activating, and nitric oxide-releasing properties for oral mucositis prevention and oncology.
- What regulatory designations has EpicentRx received?
- FDA Fast Track for AdAPT-001 in recurrent/refractory soft tissue sarcoma combined with nivolumab or atezolizumab, and for RRx-001 in severe oral mucositis and other trials; also a US Department of Defense award for RRx-001 neuroprotection.
- What is the therapeutic focus and pipeline stage?
- Focus on oncology (solid tumors, immunotherapy resistance), side effect reduction (mucositis), and emerging areas like neuroprotection and endometriosis; both leads are in late-stage (Phase 2/3) clinical trials.
Related editorial coverage
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
- FDA Approval VX-009: Market Analysis of Oncodex's Oncolytic Virus Therapy
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
